An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

Completed · Phase 3

Conditions studied: Fibrodysplasia Ossificans Progressiva

In brief

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.

Key facts

Study ID
NCT03312634
Run by
Clementia Pharmaceuticals Inc.
People needed
107
Starts
2017-11-30
Expected to finish
2022-09-07
Last updated by the study team
2023-11-29

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.